Peakdel Molecular Limited

Their core work

Peakdel Molecular Limited is a UK-based private company operating in medicinal chemistry and chemical biology, with demonstrated expertise in small molecule design and therapeutic applications. Their involvement in two MSCA Innovative Training Networks — one focused on click chemistry for gene therapy, another on neurotrophin small molecule mimetics — indicates they serve as an industrial partner providing real-world drug discovery environments for early-stage researchers. As a third-party host rather than a funded participant, they contribute laboratory infrastructure, scientific mentorship, and industrial research context to academic consortia. Their work sits at the intersection of synthetic chemistry and biomedical applications, particularly in areas where chemistry must translate into therapeutic candidates.

What they specialise in

How they've shifted over time

Peakdel's two projects span 2015 to 2022, and while both sit within chemical biology, the therapeutic focus shifted between them. The earlier ClickGene project centered on nucleic acid chemistry and gene delivery — a chemistry-first perspective on genetic medicine. The later EuroNeurotrophin project moved toward CNS drug discovery, specifically mimicking protein growth factors with small molecules, which requires a more pharmacological mindset. This suggests the company broadened its therapeutic scope from gene therapy chemistry toward small molecule CNS therapeutics, though both remain grounded in the same core skill of designing molecules with biological activity.

Peakdel appears to be moving from nucleic acid–based therapeutic chemistry toward small molecule CNS drug discovery, which would make them a relevant industrial partner for future consortia targeting neurological conditions.

How they like to work

Peakdel participates exclusively as a third party — they have never led or co-led an H2020 project. This is characteristic of small industrial companies that engage with academia through MSCA networks by hosting PhD researchers rather than driving project management. They connect into large consortia (31 partners across both projects) but their operational role is likely focused: providing a laboratory environment, industrial mentorship, and real-world drug discovery exposure to network fellows.

Peakdel has connected with 31 unique consortium partners across 11 countries through two MSCA training networks. Their network is broad in geography but shallow in depth — they have not repeated partnerships with the same organisations, which is typical of ITN structures where each network recruits a fresh consortium.

What sets them apart

Peakdel occupies a niche as a small UK private company that bridges academic chemistry research and industrial drug discovery, specifically through researcher training rather than contracted R&D. For consortium builders assembling MSCA training networks in chemical biology or medicinal chemistry, Peakdel offers a proven track record as an industrial host — a role that is harder to fill than it looks, since it requires genuine lab capacity and scientific mentorship. Their dual coverage of gene therapy chemistry and CNS small molecules makes them unusually versatile for a company of their apparent size.

Highlights from their portfolio

• EuroNeurotrophin
  A pan-European training network targeting neurotrophins — proteins critical to neuron survival — with small molecule mimetics, placing Peakdel at the industrial frontier of CNS drug discovery research.
• ClickGene
  One of the earliest MSCA networks dedicated to click chemistry in gene therapy, situating Peakdel in a high-interest therapeutic chemistry field before it became mainstream.